Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 121.97B, Vertex Pharmaceuticals(VRTX) trades at $475.00. The stock has a price-to-earnings ratio of 31.33.
As of 2026-02-27, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $474.59 and $483.63. The current price stands at $475.00, placing the stock +0.1% above today's low and -1.8% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 1.31M, compared to an average daily volume of 1.5M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Key Points Centessa Pharmaceuticals has a promising candidate, but plenty of work remains before it can launch it. Vertex Pharmaceuticals has a rich lineup of...
A clear thread runs through Reshma Kewalramani’s career, connecting her start as a kidney doctor, her years leading drug research and development at Amgen, and...
Vertex Pharmaceuticals reported past full-year 2025 results with revenue rising to US$12.00 billion from US$11.02 billion and net income improving to US$3.95 bi...
Analyst ratings
76%
of 33 ratingsMore VRTX News
Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatil...
Key Points Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still h...
Key Points Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitab...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.